Meeting Mic
Download on the App Store

Meeting Mic episodes

  • Highlights from ACR Convergence 2022
    In this episode of Meeting Mic, we bring you the highlights and insights from the ACR Convergence 2022, as well as Healio's top headlines from the meeting. Alfred Kim, MD, discusses some key take-home points from the Long COVID presentation :18 Giovanni Adami, MD, reviews the impact of tofacitinib on fracture risk in patients with rheumatoid arthritis and the effect of glucocorticoids on bone density. 3:39 Leonard Calabrese, DO, gives a long-view of the meeting and the sessions he attended. 6:06 Paul Emery, MD, discusses results of a phase 2 study of peresolimab for adults with rheumatoid arthritis. 9:32 Read the full coverage here: https://www.healio.com/news/rheumatology/ 20221112/understanding- of-long-covid-shifting-at- breakneck-speed https://www.healio.com/news/rheumatology/ 20221122/bonesafe-glucocorticoid- dose-hard-to-find-in- rheumatic-musculoskeletal- diseases https://www.healio.com/news/rheumatology/ 20221121/pd1-agonist-generates-a-bit-of-excitement- in- rheumatoid- arthritis ACR: Varicella vaccine strongly recommended in all immunosuppressed adults 'Anatomy inventory' fosters more inclusive care for transgender, non-binary patients 'Strange times': Prescribing methotrexate legally 'low risk' Post-Roe Disclosures: Adami reports consultant roles with Amgen, BMS, Eli Lilly, Fresenius Kabi, Galapagos, Theramex and UCB. Calabrese reports consultant roles with AstraZeneca and GSK. Emery reports relationships with AbbVie/Abbott, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Galapagos, Gilead, Novartis, Pfizer, Roche and Samsung. Kim reports no relevant financial disclosures.
    17 min
  • Highlights from ASCO Annual Meeting 2022

    In this episode of Meeting Mic, we bring you pearls and perspectives from the 2022 ASCO Annual Meeting, as well as Healio's top headlines from the meeting.

    Stephen M. Ansell, MD, PhD, discusses efforts to identify new upfront treatment regimens to help extend OS in patients with relapsed or refractory classical Hodgkin lymphoma. :25

    Lorenzo Cohen, PhD, shares his thought on the impact of acupuncture regimens on xerostomia and patients' quality of life. 5:26

    Bradley J. Monk, MD, discusses the results of a study on the use of rucaparib monotherapy among women with advanced ovarian cancer 10:37

    Christopher Manz, MD, MSHP, provides an overview of the results of the randomized PROStep trial, which assessed whether remote patient-reported symptoms and passive activity monitoring could improve patient-clinician communication about symptoms and functional status of patients with cancer. 18:09

    Luke Maese, DO, discusses the results of the Children's Oncology Group AALL1931 study, its rationale, the potential implications of the findings and the questions that must be addressed in future research. 21:04

    Read the full coverage here:

    https://www.healio.com/news/hematology-oncology/20220603/firstline-brentuximab-vedotin-regimen-extends-os-in-advanced-classical-hodgkin-lymphoma

    https://www.healio.com/news/hematology-oncology/20220609/acupuncture-benefits-patients-with-radiationinduced-xerostomia

    https://www.healio.com/news/hematology-oncology/20220606/rucaparib-shows-efficacy-as-firstline-maintenance-therapy-in-ovarian-cancer

    https://www.healio.com/news/hematology-oncology/20220610/more-work-to-do-in-oncology-to-collect-useful-data-about-symptoms-functional-status

    https://www.healio.com/news/hematology-oncology/20220611/intramuscular-recombinant-erwinia-asparaginase-active-safe-in-leukemia-lymphoma-subsets

    Dostarlimab shows efficacy as curative-intent treatment in rectal cancer subset

    Source: Cercek A, et al. Abstract LBA5. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

    Trastuzumab deruxtecan extends survival in HER2-low metastatic breast cancer

    Source: Modi S, et al. Abstract LBA3. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

    Disclosures:

    Ansell reports research funding to his institution from ADC Therapeutics; Affimed Therapeutics, AI Therapeutics, Bristol Myers Squibb, Regeneron, Seagen and Trillium Therapeutics, and honoraria from Research to Practice and WebMD.

    Cohen reports no relevant financial disclosures.

    Monk reports relationships with Clovis Oncology, Merck, Roche/Genentech and several other pharmaceutical companies.

    Manz reports no relevant financial disclosures.

    Maese reports consultant and speakers bureau roles with Jazz Pharmaceuticals.

    29 min
  • ATS 2021 International Conference

    In this episode of Meeting Mic, we bring you pearls and perspectives from the American Thoracic Society 2021 International Conference, as well as Healio's top headlines from the virtual meeting.

    Leonard Bacharier, MD, discusses results of the VOYAGE study of dupilumab in children with asthma :35

    Dennis Hwang, MD, shares data from a study that looked at severe obstructive sleep apnea and COVID-19 risk 7:11

    Alayna Tackett, PhD, discusses results of her analysis of e-cigarette use and the association with wheeze and shortness of breath, even in young adults who don't smoke 10:25

    Michael Wechsler, MD, shares data from the LIBERTY ASTHMA TRAVERSE Extension Study, which assessed long-term maintenance of oral corticosteroid reduction and efficacy with dupilumab in patients with asthma 14:01

    Ana Hernandez Cordero, PhD, discusses data from an integrative genomic analysis of potential genetic risk factors for COVID-19 23:15

    Read the full coverage here:

    https://www.healio.com/news/pulmonology/20210519/tezepelumab-reduces-exacerbations-in-broad-population-of-patients-with-severe-asthma

    https://www.healio.com/news/pulmonology/20210518/multiple-disease-progression-events-less-likely-with-continued-inhaled-treprostinil

    https://www.healio.com/news/pulmonology/20210517/monoclonal-antibody-cocktail-cut-covid19-hospitalization-death-by-70-in-outpatient-setting

    https://www.healio.com/news/pulmonology/20210516/fauci-covid19-vaccines-the-bright-light-of-this-extraordinary-challenge

    Disclosures:

    Bacharier reports he received speaker fees from AstraZeneca, GlaxoSmithKline, Regeneron and Sanofi; was on the data safety monitoring board for Cystic Fibrosis Foundation and DBV Technologies; and received research support from NIH, Sanofi and Vectura.

    Hernandez Cortez reports funding from MITACS and Providence Health Center.

    Hwang reports that efforts for the study were supported by grants from the American Academy of Sleep Medicine Foundation and from internal Kaiser research support.

    Tackett reports no relevant financial disclosures. The research was supported by the National Heart Lung and Blood Institute from the NIH and the Oklahoma Tobacco Settlement Endowment Trust.

    Wechsler reports he received consultant fees from AstraZeneca, Amgen, Boehringer Ingelheim, Cohero Health, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi, Sentien and Teva.

    35 min
  • Hawaiian Eye 2020

    In this episode, we bring you pearls and perspectives from Hawaiian Eye 2020.

    • Ashley Brissette, MD, MSc, FRCSC, considers the importance of testing for inflammation and dry eye before performing cataract surgery :17
    • Ryan Bleeks, of Sun Ophthalmics, shares an update on Cequa - cyclosporine ophthalmic solution 0.09% - for the treatment of dry eye disease 2:45
    • Jay S. Pepose, MD, PhD, discusses treatment options for varicella zoster 4:04
    • Jennifer M. Loh, MD, discusses the impact that sharing a meibomian gland image can have in patient treatment 6:04
    • Brandon Ayres, MD, examines the use of the FDA-approved epi-off corneal cross-linking procedure 7:16
    • John P. Berdahl, MD, discusses the benefits of compounded medications that are unique to ophthalmology 10:18
    • Femida Kherani, MD, shares pearls for incorporating dermal fillers and neuromodulators 12:13
    • Craig N. Piso, PhD, shares pearls for improving ophthalmic technician performance 13:01
    • Tom Mitro, president and chief operating officer of Aerie Pharmaceuticals, discusses results of the MOST phase 4 trial 14:30
    • Richard S. Davidson, MD, discusses surgical correction for keratoconus 15:43
    • Steven D. Vold, MD, discusses the use of Vyzulta -latanoprostene bunod ophthalmic solution 0.024% by Bausch + Lomb 17:00
    • Thanks for listening 18:45

    Disclosures: Ayres reports being a paid consultant to Glaukos. Bleeks is an employee of Sun Ophthalmics. Brissette reports being a paid consultant to Alcon and Zeiss. Loh reports being a paid consultant to Sight Sciences. Mitro is president and COO of Aerie Pharmaceuticals. Vold reports being a paid consultant to Bausch + Lomb. Davidson, Kherani, Pepose and Piso report no relevant financial disclosures.

    19 min

About Meeting Mic

From the publisher's feed

While annual major scientific meetings are the venue to stay up-to-date in your clinical area, it is near impossible to attend all breaking news sessions. Through interviews with experts, Healio's…

More shows like Meeting Mic

Healio Rheuminations by Adam J. Brown, MD

Healio Rheuminations

121 Listeners

Eye Care Out Loud by Darrell White

Eye Care Out Loud

9 Listeners

Gut Talk by Sameer K. Berry, MD, and William D. Chey, MD

Gut Talk

31 Listeners

Unmasking COVID-19 by Healio

Unmasking COVID-19

30 Listeners

Oncology Overdrive by Shikha Jain, MD

Oncology Overdrive

15 Listeners

Eye Care Insider by Joshua Mali, MD

Eye Care Insider

5 Listeners

Vital Capacity by Abhishek Bhardwaj, MD

Vital Capacity

13 Listeners

Mend the Gap: Equity in Medicine by Healio

Mend the Gap: Equity in Medicine

6 Listeners

Eyeluminaries by John Hovanesian, MD, FACS and Jim Mazzo

Eyeluminaries

5 Listeners